Using Novel Technology for Developing New Ways to Deliver and Experience New Medicines
Our Pharmaceutical Medicines
CURE is conducting clinical research on a variety of active pharmaceutical ingredients (APIs), both internally and through partnerships, mostly utilizing our proprietary drug delivery platform CUREfilm®. The focus of our programs is addressing novel approaches to meaningful disease states that are either undercovered or underappreciated by larger pharmaceutical players. These areas have high barriers to entry and benefit from drug delivery expertise. Our strategy is to capture these opportunities wherever possible using the 505(b)2 regulatory pathway, which enables us to seek regulatory approval at a faster pace than other pathways.
- PRODUCT DEVELOPMENT/DRUG DELIVERY EXPERTISE
- PROPRIETARY PLATFORM TECHNOLOGY
- STRATEGIC FOCUS ON LIKELIHOOD OF SUCCESS
- ABBREVIATED REGULATORY PATHWAY – 505(b)2
- DIFFERENTIATED DOSAGE FORMS/ROUTE OF ADMIN.
Novel Delivery of Known APIs
Unmet Need Applications
Active ingredients in the CUREfilm® dose form can be either pre-solubilized within its matrix or encapsulated, or both for more effective absorption and/or sustained release. As oral thin films quickly dissolve, no water is required for their administration, improving patient compliance – especially among the elderly, children, and in conditions where patients have difficulty in swallowing.
ENDOCANNABINOID SYSTEM RESEARCH
Cannabinoid research presents a unique opportunity for CURE, having successfully proved that our novel delivery system CUREfilm® improves the bioavailability of cannabinoids in the body. Many large pharmaceutical companies are researching the potential therapeutic benefits of cannabinoids such as Tetrahydrocannabinol (THC) and cannabidiol (CBD). CURE is conducting on-going clinical research on cannabinoids, both internally and through partnerships.
Cancer Research Collaboration with Technion-Israel Institute of Technology
Researchers from CURE’s Pharmaceutical Cannabinoid Division and Technion’s Laboratory of Cancer Biology and Cannabinoid Research are working together to research and identify how varying cannabinoid compounds within cannabis strains can affect various cancer subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimize treatment efficacy.